{"id":"W4405998776","doi":"10.1016/s2213-2600(24)00407-7","title":"Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Hospital for Sick Children","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Deutsche Forschungsgemeinschaft; Vertex Pharmaceuticals; Cystic Fibrosis Trust; Department of Health and Social Care; National Institute for Health and Care Research; Insmed; AstraZeneca; UK Research and Innovation; Cystic Fibrosis Foundation Therapeutics; Great Ormond Street Institute of Child Health; Cystic Fibrosis Canada; European Respiratory Society; American Thoracic Society","keywords":"Ivacaftor; Medicine; Tolerability; Cystic fibrosis; Clinical endpoint; Clinical trial; Adverse effect; Internal medicine; Cystic fibrosis transmembrane conductance regulator","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002765085,0.0005461258,0.001345266,0.0002093828,0.0002550164,0.0007839036,0.0005119601,0.0008111913,0.003887795],"category_scores_gemma":[0.00170891,0.0002213459,0.002819148,0.0002578677,0.000437936,0.0006467754,0.0003195638,0.001812401,0.0004177006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006881475,"about_ca_system_score_gemma":0.001444236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001080244,"about_ca_topic_score_gemma":0.004537955,"domain_scores_codex":[0.9989141,0.0006509763,0.00006737809,0.0001317591,0.0001016317,0.0001341619],"domain_scores_gemma":[0.9985439,0.0003652808,0.0005303536,0.00009485133,0.000104021,0.0003617263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8825353,0.004562527,0.02390236,0.002207238,0.006471428,0.0002703977,0.0001760576,0.001253226,0.009324034,0.0003979675,0.003855342,0.06504407],"study_design_scores_gemma":[0.7971006,0.1402959,0.05025071,0.000434356,0.003967559,0.0005644152,0.00009508579,0.0007568966,0.001454541,0.0002747638,0.004763835,0.00004140429],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806779,0.01271526,0.0004394162,0.0005854816,0.0001232327,0.001361806,0.002240369,0.00004802153,0.00180841],"genre_scores_gemma":[0.989924,0.004030115,0.001131881,0.0005438352,0.0001021817,0.001185171,0.001982194,0.00001831767,0.001082295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003887795,"threshold_uncertainty_score":0.01462334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05907750964551386,"score_gpt":0.3834071557346643,"score_spread":0.3243296460891505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}